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Abstract
The brain is a complex organ in charge of regulating the homeostasis of our body and
behaviors such as motivation, reward, memory, and movement control, between others.
These behaviors are regulated by dopaminergic neurons, which can be modulated by
several stimuli throughout the life of an individual. For example, early exposure to sex
hormones or endocrine disruptors during critical period of neuronal development
affects dopaminergic pathways permanently, producing some disorders such as drug
addiction. On the other hand, current knowledge regarding neurodegeneration in
Parkinson and Alzheimer diseases pointed out the neuroprotection that estradiol can
exert, but contradictory information can also be found in the literature. To know the
underlying mechanisms that are related to the above mentioned diseases will help to
improve health policies and treatments development.
Keywords: sex hormones, neonatal programming, dopaminergic circuit, neuroprotection,
drug addiction, Alzheimer, Parkinson disease
1. Introduction
In the current world, humans are exposed to different compounds that can exert deleterious
modifications in their bodies, taking special attention of the short- and long-term effects of
endocrine disruptor chemicals, which mimic or block hormonal activity. Endocrine disruptor
chemicals are natural or synthetic molecules that can alter the endocrine homeostasis, especially
if exposure to these molecules is during critical developmental windows [1]. These compounds
are used in plastic industries, chemical, and pharmaceutical industries, and for different events
that are bioavailable in the environment affecting animals and humans. Endocrine disruptors
exert their action through different pathways that converge on the molecular targets such as
hormone receptors, enzymatic pathways involved in biosynthesis and metabolism of endobiotics
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in endocrine, reproductive, and nervous system. In this sense, different brain areas are sensible to
the action of endocrine disruptors and sex hormones due to the presence of its receptors that can
modulate the synaptic transmission and neuronal survival. In this regard, nuclear receptors for
sex hormones are ligand-activated transcriptional factors that regulate different neural process
such as neurodevelopment and behaviors. Alterations in hormonal homeostasis (e.g., aging) or
signaling (e.g., exposure to agonists or antagonists of sex hormone receptors) may induce the
onset of diseases before mentioned, affecting lifespan, quality of life, and high medical costs.
Worldwide, drug abuse has increased dramatically, especially in susceptible populations such
as youth. However, human and animal studies show that not all drug consumers become
addicts. In addition, it has determined sex differences in behaviors related to motivation,
reward, and cognition, among others. Clinical observation has shown that children who have
developed precocious puberty show an increase in risky behaviors such as drugs abuse, sexual
risk, and anti-social behaviors in adolescence.
Also, when Parkinson (PD) and Alzheimer disease (AD) is analyzed, it observed a sex differ-
ence in terms of prevalence, which draws the attention to the possible role of sex hormones in
the onset of these pathologies. In this term, meta-analysis has shown that males have aug-
mented prevalence of PD than women, overall in the age range of 50–59 years (134 per 100,000)
compared to women (41 per 100,000) [2]. However, the prevalence of AD is greater in women
compared to men, considering different age range and ethnicity [3, 4].
In this chapter, we will discuss about the exposure to abnormal levels of sex hormones, due to
metabolic alterations or endocrine disruptor chemicals, during critical period of neurodeve-
lopment; and based on clinical evidence and current scientific knowledge, we will discuss the
mechanisms involved in the development of drug addiction, Alzheimer and Parkinson dis-
ease, and the sex differences observed between patients.
2. Programming: early exposure to sex hormones
Programming concept was defined by Lucas as the physiological redirection of a tissue or
organ by a deleterious stimulus in a sensitive period of development produces adverse func-
tional changes in adulthood [5]. Currently, research in programming has been focused in the
study of stimuli that affects sensitive periods of development such as prenatal and neonatal
stages.
In that sense, experiments are carried out in female rats, where precocious puberty is induced
by neonatal exposure to estradiol valerate, is accompanied by increased catecholamine content
in the adrenal gland, noradrenaline content in the ovary and reproductive alterations in the
adulthood [6]. Using the same model of neonatal administration of estradiol valerate [7], it
observed an increase in dopamine (DA) and noradrenaline content in dopaminergic neurons
of tuberoinfundibular [8], nigrostriatal, and mesolimbic pathways [9] of the adult. Indeed,
neonatal administration of estradiol valerate and testosterone propionate increases DA content
and tyrosine hydroxylase (TH), (rate limiting enzyme of dopamine synthesis) expression in
substantia nigra (SN), and ventral tegmental area (VTA) of adult male rats [10]. Others works
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have shown that neonatal administration of testosterone reduces spatial memory and TH
positive terminals in prefrontal cortex in an animal model of attention deficit disorder with
hyperactivity [11].
In recent years, it has been shown that environmental pollutants (being most of them chemical
disruptors) produce a myriad of effects in the brain [12]. For example, in rats, neonatal and
postnatal administration of bisphenol A produce an increase of spontaneous locomotion
behavior associated with the decreased immunoreactivity for TH in SN and decreased expres-
sion of dopamine transporter (DAT) in midbrain nuclei [13].
Sex hormone levels affect cortical and subcortical brain areas, especially in sensitive periods of
development in childhood and adolescence [14]. In this regard, dopaminergic brain areas such
as SN, VTA, and hypothalamus are sensitive to the effects of sex hormones because they
express estrogens and androgens receptors [7, 15, 16].
It has been demonstrated that exposure to a single dose of sex hormones during the neonatal
period can change the profile expression of DA [8]; in fact, when female rats are exposed to a
single dose of estradiol during the neonatal period, DA levels are increased in the ventrome-
dial hypothalamus–arcuate nucleus, but not the exposure to testosterone, during adult life [8].
In addition, when male rats are exposed to estradiol or testosterone, DA levels and TH
expression are increased in substantia nigra-ventral tegmental in addition to increased dopa-
mine release in nucleus accumbens. This effect is not seen when rats are exposed to a
nonaromatizable androgen, dihydrotestosterone, suggesting an estrogenic mechanism involv-
ing increased TH expression, either by direct estrogenic action or by aromatization of testos-
terone to estradiol in substantia nigra-ventral tegmental area [10].
2.1. Long-term epigenetic programming of the dopaminergic circuit
The programming is exerted through epigenetic modifications, which comprised DNA meth-
ylation and post-translational histone modifications, interacting with regulatory proteins and
noncoding RNA to reorganize the chromatin in active or inactive domains (euchromatin or
heterochromatin), being possible to be inherited from one generation to another without
subsequent exposure to the endocrine disruptor [17]. The normal development of mammals
involves the activity of DNA methyl transferase (DNMTs) to determine the de novo methyla-
tion, where DNMT3A and DNMT3B are involved, and to maintain the methylation pattern in
the genome, where DNMT1 is involved. The expression levels of these enzymes are highly
regulated during specific stages of life [18], and therefore, the impact of the exposure to
endocrine disruptors and the consequences over the offspring are alarming.
In this view, in humans the social alcohol drinking during periconceptional or pregnancy
period may induce changes in the promoter methylation of DAT in mothers and their babies.
Specifically, using peripheral blood from mothers or cord blood from newborns, they found
that alcohol intake decreases the methylation level of the locus-specific DAT promoter region
of the parents and newborns [19]. However, these findings are controversial, since also found a
decrease of DAT mRNA expression in drug addicts (to opioid drugs) compared to control
subjects, but not in the methylation pattern of DAT promoter [20]. One of the methodological
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factors that could determine this difference is from where the samples are obtained, in the case
of the peripheral blood, it is not a direct measurement of DAT expression in brain.
3. Sex hormones, dopaminergic neurotransmission, and addiction
Worldwide, drugs of abuse have increased dramatically, especially in susceptible populations
such as youth. However, human and animal studies show that not all drug consumers become
addicts [21, 22]. Lately, it has been determined differences in behaviors related to motivation
reward and cognition between women and men (for review see 23). Accordingly, sex hormone
levels affect cortical and subcortical brain areas, especially in sensitive periods of development
in childhood and adolescence [14]. In this regard, dopaminergic brain areas such as SN, VTA,
and hypothalamus are sensitive to the effects of sex hormones because they express estrogens
and androgens receptors [7, 15, 16]. Interestingly, sex hormones induce opposite effects
between female and males. While estrogens increase the expression of tyrosine hydroxylase
in SN and VTA of adult female rats [24], androgens such as testosterone and dihydrotestoster-
one reduce TH expression in the same brain areas in adult male rats [25]. However, in
adolescent male rats, androgens increase TH expression in SN [26].
In humans, it has been observed that an excess of testosterone levels during prenatal stage is
related with the development and maintenance of alcohol dependence during adolescence and
adulthood [27, 28]. Children who have developed precocious puberty (an early activation of the
reproductive axis leading to the onset of puberty closer to 8, 9 years in girls and boys, respec-
tively) shows an increase in risky behaviors such as drugs abuse, sexual risk, and anti-social
behaviors in adolescence [29]. Many of these behaviors and the neuroendocrine pathways that
regulate them are sexually dimorphic. These sex dimorphisms reflect adaptive differences for
behavioral strategies in coping as a result of sexual selection. Disruptions in these behaviors
may lead to reduced social adaptation and impaired responsiveness to environmental
demands [30]. On the other hand, the exposure to several environmental pollutants, with
neuroendocrine activity, has been associated with behavioral effects. For example, genistein (a
phytoestrogen produced by legumes and present in soy bean-based food) increases locomotor
activity in males, ethinylestradiol (a synthetic estrogen used as contraceptive) affects response
to reward in females and bisphenol A, an endocrine disruptor, increases anxiety and sexual
behavior in males (for review see [12]). In summary, our brain is modulated by sex hormones
(or exogenous compounds) and depending on the stage of development, this interaction could
affect the organization and activation of neural systems (for review see [31–33]). The alteration
of sexually-dimorphic behaviors may be relevant for concerns regarding the increased devel-
opmental, cognitive, and⁄or emotional disabilities reported over the past 30 years [34].
Some studies of enrichment and deprivation of sensory inputs to the brain have provided
information regarding the role of experience on the development of the brain. These studies
suggest widespread effects of experience on the complexity and function of the developing
system, while the deprivation studies document the capacity for neural reorganization within
particular sensory systems [35]. These studies suggest that plasticity in developing neural
systems can modulate the capacity to develop fundamentally different patterns of organization
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and function in response to injury. Therefore, the neurochemical interaction and environmental
aspects can modulate the pathophysiological processes that determine the development of
neurodegenerative events [36] (Figure 1).
The mesocorticolimbic system comprises the midbrain dopaminergic projection from the VTA
to the nucleus accumbens (NAcc) [23, 37] and prefrontal and orbitofrontal cortexes [38]. One of
the most important neurotransmitters in mesocorticolimbic system is DA, which is released in
response to natural rewarding stimuli as food [39] or sex [40]. Drugs of abuse produce an
increase in DA release in NAcc and striatum [41]; however, the magnitude and duration of this
effect are much greater than with natural reinforces [42]. This acute supraphysiological DA
release induced by drugs of abuse in the NAcc exherte its actions through the activation of the
DA receptor type 1 (D1 receptor), leading to early gene products induction (e.g., cFos) [43]. In
situ hybridization studies have demonstrated the expression of estrogen receptors (ESR1,
ESR2) and androgen receptors in SN-VTA [16, 44]. Using immunohistochemistry, it has been
shown that ESR2 is expressed in high proportion in TH positive neurons of the VTA, whereas
Figure 1. Schematic representation of the influence of neuroactive compounds like estradiol, testosterone, DHT, genistein,
and bisphenol A on brain areas. These compounds can cross the blood–brain barrier, reaching brain areas that are related
to cognition and learning (prefrontal cortex and hippocampus), movement (striatum), reward (VTA), social emotional
(amygdala), the endocrine system (hypothalamus). Abbreviations: E2, estradiol; T, testosterone; DHT, dihydrotestoster-
one; PFC, prefrontal cortex; VTA, ventral tegmental area.
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androgen receptor is expressed in high proportion in TH positive neurons of NAcc [15]. Thus,
sex hormones can regulate the expression of Tyrosine hydroxylase; specifically, estrogens can
increase the expression of TH in SN and VTA of adult female rats [24], while androgens reduce
TH expression in the same brain areas in adult male rats [25]. Noteworthy, in adolescent male
rats, androgens increase TH expression in SN [26], suggesting a mechanism that depends on
the physiological/hormonal context. The effects of sex hormones are mediated by the activa-
tion of specific receptors expressed in cell bodies of midbrain dopaminergic neurons and its
limbic projections. The dopamine transporter, DAT, is a protein that mediates the active
reuptake of dopamine from the synapse and is a principal regulator of dopaminergic neuro-
transmission, dopamine receptor 1 and 2 (D1 and D2, respectively) are modulated by 17β-
estradiol and testosterone. Experiments using ovariectomized adult rats have shown a signif-
icant reduction of DAT levels in the NAcc and Striatum, which is restored to normal levels
after E2 replacement or the use of diarylpropionitrile (a selective ERβ agonist) and tamoxifen
(selective estrogen receptor modulator) [45–48]. In the same model, levels of D1 in mPOA are
decreased after E2 replacement [49]. Noteworthy, immunoreaction to D2 is not affected by E2
replacement, when is measured using immunohistochemistry. However, when western blot is
used, levels of D2 are apparently increased in mPOA and PLC [49]. In NAcc, D2 levels are
significantly increased in the NAcc and striatum of ovariectomized rats and E2 replacement
reduced D2 receptors to lower levels than in controls rats [48].
It has been shown that circulating levels of female and male sex hormones modulate the
mesocorticolimbic system, regulating the addictive behavior. Women in reproductive age
who are users of drugs of abuse show greater rate of escalation of drug use than men [50],
leading to the establishment of the addictive behavior quickly [51]. On the other hand,
depending on circulating levels of sex hormones in menstrual cycle, the reward effects of
psychostimulant drugs such as amphetamine are more potent in follicular phase when estra-
diol levels are higher than luteal phase, when progesterone levels are higher [52, 53].
Exposure to hormone disruptors has shown to produce effects on the behavior of animals.
Thus, the prenatal administration of bisphenol A to pregnant mice and postnatal administra-
tion to offspring until postnatal day 15 produces anxiolytic behavior in elevated plus-maze
and open field tests [54]. Interestingly, this behavior has been related to a significant decrease
of DAT in striatum and NMDA receptor in frontal cortex [54]. Silverman and Koenig [55]
showed the involvement of ESR2 in the reinforcement induced by low doses of amphetamine
in female rats. In this work, ovariectomized female rats do not show conditional place prefer-
ence to amphetamine compared with intact female rats. The replacement with estradiol or
estradiol plus progesterone reestablishes the conditioned place preference induced by amphet-
amine in ovariectomized rats [55]. Interestingly, the authors found that conditioning with
amphetamine was significant in the ovariectomized groups that were administered with
estradiol or the ESR2-specific ligand DPN. These results provide new evidence of the specific
requirement of ESR2 in response to drugs of abuse [55].
3.1. Attention-deficit/hyperactivity disorder (ADHD)
Regarding the behavioral effects produced by the administration of androgens, it has been
observed that the neonatal administration of testosterone in spontaneously hypertensive rats
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(SHR) (an animal model of attention-deficit hyperactivity disorder [ADHD]) decreases cogni-
tive function and TH immunoreactivity in prefrontal cortex [11]. In this work, the authors
implanted at postnatal day 1 pellets of testosterone in SHR rats, observing at postnatal day 45,
through the Morris water maze test, an increased latency to find the platform. The authors
conclude that the administration of androgens in neonatal period may predispose to ADHD-
like behaviors in the adulthood.
With regard to pharmacological therapies of ADHD, animal studies and case reports have
suggested that methylphenidate exerts adverse effects on gonadal hormones. In this case, meth-
ylphenidate could be altering testosterone levels in children with attention-deficit/hyperactivity
disorder through the comparison of those with or without methylphenidate treatment [56].
Recently, prospective study conducted in Taiwan that included 203 ADHD patients with a
mean age of 8.7 years (boys: 75.8%). After the initial recruitment, 137 received daily methyl-
phenidate treatment and 66 were assessed through naturalistic observation (nonmedicated
group). During the study period, salivary testosterone levels did not significantly change in
the treated group (P = 0.389) or in the nontreated group (P = 0.488). After the correction for
potential confounding effects of age and sex, salivary testosterone levels still remained
unchanged in the treated and nontreated groups during the 4-week follow-up [57]. Findings
suggest that the short-term treatment with methylphenidate at usual doses does not signifi-
cantly alter salivary testosterone levels in attention-deficit/hyperactivity disorder patients.
Future studies should clarify whether long-term methylphenidate treatment disrupts testos-
terone production as well as the function of the reproductive system.
In summary, these evidences indicate that sex hormones play an important role modulating
the mesocorticolimbic system and behavioral, neurochemical, and neuroplastic effects of drugs
of abuse.
4. Sex hormones and Alzheimer disease
During the menopause in women or andropause in men, there is a normal decrease in sexual
hormones, due to the loss of ovarian sex hormones (estrone, estradiol, and progesterone) or to
a decrease in testosterone levels, correspondingly. Noteworthy, postmortem analysis has
shown lower brain levels of estrogens in women with AD, and lower levels of androgens in
men with AD compared to nonAD patients. Specifically, studies performed in caucasic female
subjects with neuropathological diagnosis of AD, according to Braak stages V–VI, with the
absence of other neuropathologies (ranging in age from 61 to 90 years old) show a decrease of
two times in estrone levels (midfrontal gyrus samples) when compared to controls, but not in
estradiol, testosterone, or dihydrotestosterone (DHT) levels [58]. However, when male subjects
with neuropathological diagnosis of AD, according to Braak stages V–VI, are analyzed (rang-
ing in age from 50 to 97 years old) estradiol or estrone levels are not different between AD
subjects and controls, but there is a decrease in androgen levels in AD patients, compared to
controls [58]. Thus, it is proposed that the sex hormone decrease observed in brain samples
from AD patients is not just related to the normal decrease in gonadal synthesis, but also to a
decrease in local brain steroidogenesis [58, 59].
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Supporting that, the premenopausal bilateral oophorectomy (surgical menopause), which
induces early menopause through an abrupt decrease in circulating estrogen levels in young
women, has shown lights about the role of sex hormones, its decline during the menopause
and correct timing of hormonal replace therapy [60, 61]. Thus, in a study where 1884 women
were followed longitudinally for upto 18 years (natural menopause n = 1277, surgical meno-
pause n = 607) relating the onset of menopause (natural or surgical) to cognitive decline and
AD. According to the study, surgical menopause at earlier age was associated with the decline
in cognition (decline in episodic and semantic memory) as well as a greater level of Alzheimer
disease in women who survived free of dementia to a mean age of 78 years [61]. Noteworthy,
when the use of hormone therapy was considered in the study, a protective role was found
when the treatment was administrated within 5-year perimenopausal period for at least
10 years: less decline in visuospatial ability, episodic, and semantic memory, but no influence
over the onset of AD [61].
In women, it has been determined that the hormonal treatment with estradiol has more
protective effects than the treatment with conjugated equine estrogen. Noteworthy, many
studies have pointed out that the hormonal treatment needs to start during what is called a
“window of opportunity”, since the protective effects of estradiol treatment depend on when
hormonal treatment is started. In particular, hormonal treatment needs to start during the
perimenopause period (i.e., under age of 65 years). During this period is necessary to maintain
a constant treatment (not withdraw), since doing so could decrease the memory improvement
obtained by the hormonal treatment [62]. Verbal memory is enhanced with the treatment with
E2. Although there are many studies supporting the benefits of hormonal treatment, there are
other studies that are against this statement. The window of efficient therapy depends on the
capacity of the brain to respond to sexual hormones, and the presence of receptors in brain
areas related to memory. This decrease is related to the normal decrease in sexual hormones
due to aging, in man and woman. In that term, HT is focused on to keep the hormonal levels
constant, so the brain cannot lose its responsiveness to hormones. Basic studies have shown
that the role of estrogens or molecules like tamoxifen, a selective estrogen receptor modulator
used as hormone therapy, may induce/modulate the dopamine system, inducing neuropro-
tection. In that term, the use of tamoxifen in murine AD model has shown an increment in
dopamine content in striatum, and an improvement in memory tasks [63].
Recently, seven prospective cohort studies with a total of 5251 elderly men and 240 cases of
Alzheimer’s disease were included into the meta-analysis of AD follow-up. Meta-analysis using
random effect model showed that low plasma testosterone level was significantly associated with
an increased risk of Alzheimer’s disease in elderly men (RR = 1.48, 95% CI 1.12-1.96, P = 0.006)
[64]. This decrease is in direct relation with appearance of Aβ plaques in the brain, since androgen
and estrogens can regulate the amount of Aβ through the modulation of signal transduction or
enzymes related to the clearance of Aβ, like insulin-degrading enzyme, neprilysin, endothelin-
converting enzymes 1 and 2, and angiotensin-converting enzyme. In that term, animal models of
gonadectomy, to reduce the sexual hormones, have shown a direct relationship between the
hormonal decrease and the increased amount of Aβ in the brain [65–67]. Also, in this type of
models, the hormone therapy reduces the levels of Aβ and improves the memory. Thus, the
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formation of Aβ plaques can be induced by a reduction in sensitivity to estrogens or androgens
due to long periods of low steroid hormones synthesis from gonads, modifying themechanism of
amyloid precursor protein elimination that is regulated by estradiol.
Clinical approach involved the estradiol and its role in maintaining brain architecture and
metabolism, and chronically low levels of estradiol associated to anovulation may impair brain
health. In women with functional hypothalamic amenorrhea, alterations in the thyroid axis
impair neurogenesis and synaptic connectivity [68].
5. Sex hormones and Parkinson disease
Parkinson disease is a progressive neurodegenerative, multisystemic disorder characterized by
a combination of motor symptoms like resting tremors, rigidity, bradykinesia, and postural
abnormalities [69]. In addition, there are cognitive, neuropsychiatric, sleep, autonomic, and
sensory disturbances associated to PD, which are related to the degeneration of serotoninergic
neurons of the raphe nucleus, noradrenergic neurons of the locus coeruleus or cholinergic
neurons of the nucleus basalis of Meynert [70]. PD is associated to degeneration of dopamine
neurons in substantia nigra pars compacta, being PD the most common disease of dopamine
dysfunction [71].
It has been reported that higher incidence rates of PD in men are compared to women [72, 73],
and special interest has been put on sex hormones, due to its role on the regulation of
dopamine synthesis, being estradiol the main regulator of this synthesis. In addition, studies
performed to oophorectomized women, have revealed a higher risk of PD in this patients,
suggesting that the abnormal decrease in estradiol prior to the menopause can be related to the
onset of PD condition [74]. On other hand, increased exposure to endogenous estrogen can be
associated with a late onset of PD and less sever motor impairment according to a study where
579 female patients were analyzed according to menarche age, menopause age, and PD onset
age; also, delayed exposure to estrogens, through an increased age at menarche, is associated
with older age at PD onset [75].
The synthesis of estrogen differs between reproductive and nonreproductive women, being
the extragonadal tissues, like kidney, adipose tissue, skin, and brain, the main source of
estrogen in nonreproductive women. In reproductive women, the main sources are ovaries,
corpus luteum, and placenta. In men, the main source of testosterone is the testis.
As was mentioned for Alzheimer, sex hormones levels are crucial to maintain the proper
functioning of brain circuits. Regarding to that, the normal decrease of estrogen levels in
women, or testosterone in men, has been related to the onset of Parkinson. Many studies have
shown that hormonal replacement therapy can reduce the risk of PD is applied during what is
called a “window of opportunity”, which is immediately after menopause. Using the same
treatment after that period, the beneficial effects could be lost, due to a long-term hormone
deprivation reviewed by [76] (Figure 2).
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5.1. Clinical aspects in Parkinson disease
Male patients with Parkinson disease have less testosterone and estradiol than healthy males.
In a recent study, it was determined if dopaminergic therapy using levodopa and dopamine
agonist influenced testosterone levels. In this study, a cohort of 32 consecutive male patients
from the INSPECT trial were used. INSPECT is a multi-center, prospective study that primar-
ily examined the effects of short-term treatment with pramipexole or levodopa on cohort of PD
patients [77]. There were statistically significant differences in the change in free testosterone
level, increased in both the levodopa group and pramipexole group but decreased in the
untreated group at 12-weeks post-treatment. These preliminary data support the premise that
dopaminergic medications do not reduce testosterone levels in early PD patients. In a clinical
study, where male subjects were analyzed (36 PD patients and 69 age-matched controls):
prolactin levels were higher in PD subjects, compared to healthy ones. Also, concentrations of
estradiol and testosterone in the control group were higher than those found in patients. In
addition, the level of sex hormones was positively correlated with better mood and quality of
life in patients affected with PD; prolactin levels correlated negatively with sex steroid concen-
trations [78, 79]. Therefore, it is extremely necessary to determine the level of hormones that
may influence patients’ cognition, mood, and quality of life of PD patients. The more impor-
tant clinical trials that show the relationship between sex hormones and neurodegenerative
disorders are shown in Table 1.
Figure 2. Effects of estradiol and testosterone on dopamine synthesis. Neonatal exposure to estradiol or testosterone
increases TH expression in midbrain dopaminergic neurons. Abbreviations: E2, estradiol; T, testosterone.
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6. Concluding remarks
Here, we review how sex hormones (i.e., neuroactive modulators) can differentially modulate
neuronal neurodegeneration in animal and clinical models. Specifically, we provide an over-
view of the effects of sex hormones, stress hormones, and metabolic hormones on structural
Pathology Trial (N) Primary end point Treatment/Results (R) Reference
ADHD Phase III trial
(n = 203)
Salivary testosterone levels 137 received daily methylphenidate
treatment and 66 were assessed through
naturalistic observation
[57]
Alzheimer
disease
Phase II trial
(n = 240)
Plasma testosterone Meta-analysis using random effect model
showed that low plasma testosterone
level was significantly associated with an
increased risk of Alzheimer’s disease in
elderly men
[64]
Prospective
brain imaging
study
(n = 54)
2-year prospective brain
imaging study and randomized
trial of HT continuation or
discontinuation in a sample of
middle-aged postmenopausal
women (aged 49-69 years).
Continuation of HT use appears to
protect cognition in women with
heightened risk for AD when initiated
close to menopause onset
[62]
Parkinson
Disease
INSPECT trial–A
multi-center
Phase III trial
(n = 32)
Testosterone levels and motor
scores
There were statistically significant
differences in the change in
free testosterone level, increased in both
the levodopa group and pramipexole
group but decreased in the untreated
group at 12-weeks post-treatment
[77]
Phase II trial
(n = 36)
The plasma levels of oestradiol,
testosterone, prolactin and sex
hormone-binding protein were
examined in 36 patients affected
with Parkinson’s disease and in
69 age-matched control subjects,
using chemiluminescent
reactions.
The level of sex hormones was positively
correlated with better mood and quality
of life in patients affected
with Parkinson’s disease; prolactin levels
correlated negatively with sex steroid
concentrations.
[78]
Hormone
decrease
Cognitive
Impairment in
postmenopausal
women
(n = 4532)
Participants received either one daily
tablet of 0.625 mg of conjugated equine
estrogen plus 2.5 mg of
medroxyprogesterone acetate or a
matching placebo. Results demonstrate
that estrogen plus progestin therapy
increases older women’s risk for probable
dementia, including Alzheimer
[80]
Phase II trial
Functional
hypothalamic
amenorrhea
(n = 60)
Ovarian function (ovulating) Randomized to Cognitive behavioral
therapy or observation for 20 weeks
[68]
Table 1. More important clinical trials that show the relationship between sex hormones and neurodegenerative
disorders.
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plasticity and some pharmacological targets. In addition, we also discuss how sex hormones
such as estrogen and testosterone can be affected by variables such as duration and intensity of
motor and cognitive impairment. Understanding the neurobiological mechanisms underlying
the modulation of neuronal structural plasticity by intrinsic and extrinsic factors will impact
the design of new therapeutic approaches aimed at restoring physiological state and determine
some pharmacological therapies. This approach is very important for the design of phase III
clinical trial (randomized clinical trial) in the clinical practical conditions.
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